OnCo

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Advanced, first line1
Second line1
Other settings1

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersFirst lineTagraxofusp (monitor albumin for capillary leak) or pivekimab sunirine (2026); alternatives hyper-CVAD or venetoclax-based regimens; CNS prophylaxis.85

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapsedAlternative CD123 agent, venetoclax combinations, clinical trials; prognosis poor.85

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersConsolidationAllogeneic HSCT in first complete remission for eligible patients; autologous transplant in selected cases (Japanese data).73

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.